Serum Metalloproteinase 9 Levels in Patients with Coronary Artery Disease: A Novel Marker of Inflammation

Abstract

Background

The finding that expression of metalloproteinases (MMPs) is induced in atherosclerotic plaques prone to rupture suggests the possibility that patients with atherosclerotic diseases would show enhanced blood levels of MMPs and that MMPs might represent a potential inflammatory risk factor for atherosclerosis. Therefore, the present study was aimed at verifying whether MMPs may represent sensitive markers of inflammation in patients with coronary artery disease.

Methods

MMP-2, MMP-9, interleukin (IL)-6, C-reactive protein (CRP), and fibrinogen levels were measured in blood samples obtained from 66 cases with previous acute myocardial infarction and 66 control subjects similar for age, sex, and major atherosclerotic risk factors but without history or evidence of atherothrom-botic diseases.

Results

Biohumoral markers of inflammation and MMP-9 levels were significantly elevated in cases compared with controls (median values 40.6 versus 9.8 ng/mL; p < .0001), whereas MMP-2 levels did not differ between the two groups (median values 839 versus 873 ng/mL; p = .53). A direct correlation was found among MMP-9, CRP, IL-6, and fibrinogen levels. Conditional logistic regression analysis showed that MMP-9 is related to myocardial infarction (p = .006) even after adjusting for cardiovascular medications and CRP.

Conclusion

These findings suggest that measurement of serum MMP-9 levels may represent a novel marker of inflammation in patients with known coronary artery disease and might provide an index of plaque activity in this clinical setting.

Keywords

metalloproteinases atherosclerosis inflammation

Get full access to this article

View all access options for this article.

References

Ross

Atherosclerosis—an inflammatory disease.

N Engl J Med 1999; 340: 115–26.

Ridker

P.M.

Inflammation, infection and cardiovascular risk.

How good is the clinical evidence? Circulation 1998; 97: 1671–4.

Liuzzo

, Biasucci

L.M.

, Gallimore

J.R.

The prognosis value of C-reactive protein and serum amyloid A protein in severe unstable angina.

N Engl J Med 1994; 331: 417–24.

Yeghiazarians

, Braunstein

J.B.

, Askari

, Stone

P.H.

Unstable angina pectoris.

N Engl J Med 2000; 342: 101–14.

Kosuge

, Kimura

, Ishikawa

Relation between C-reactive protein levels on admission and pattern of acute myocardial infarction onset.

Am J Cardiol 2000; 86: 83–6.

Lijnen

H.R.

, Collen

Matrix metalloproteinase system deficiencies and matrix degradation.

Thromb Haemost 1999; 82: 837–45.

George

S.J.

Therapeutic potential of matrix metalloproteinase inhibitors in atherosclerosis.

Expert Opin Investig Drugs 2000; 9: 993–1007.

Libby

, Aikawa

New insights into plaque stabilisation by lipid lowering.

Drugs 1998; 56 Suppl 1: 9–13.

Kai

, Ikeda

, Yasukawa

Peripheral blood levels of matrix metalloproteinases-2 and -9 are elevated in patients with acute coronary syndromes.

J Am Coll Cardiol 1998; 32: 368–72.

10.

Kalela

, Ponnio

, Koivu

T.A.

Association of serum sialic acid and MMP-9 with lipids and inflammatory markers.

Eur J Clin Invest 2000; 30: 99–104.

11.

Puavilai

, Chanprasertyotin

, Sriphrapradaeng

Diagnostic criteria for diabetes mellitus and other categories of glucose intolerance: 1997 criteria by the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (ADA), 1998 WHO consultation criteria, and 1985 WHO criteria. World Health Organization.

Diabetes Res Clin Pract 1999; 44: 21–6.

12.

The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V).

Arch Intern Med 1993; 153: 154–83.

13.

WHO memorandum.

Classification of hyperlipidemias and hyperlipo-proteinemias.

Circulation 1972; 45: 501–8.

14.

Fuster

Mechanisms leading to myocardial infarction: insights from studies of vascular biology.

Circulation 1994; 90: 2126–46.

15.

Libby

Molecular basis of the acute coronary syndromes.

Circulation 1995; 91: 2844–50.

16.

Libby

, Schoenbeck

, Mach

Current concepts in cardiovascular pathology: the role of LDL cholesterol in plaque rupture and stabilization.

Am J Med 1998; 104(2 Suppl 1): 14S–8S.

17.

Gallis

Z.S.

, Sukhova

G.K.

, Lark

M.A.V.

, Libby

Increased expression of matrix metalloproteases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques.

J Clin Invest 1994; 94: 2493–503.

18.

Gallis

Z.S.

, Sukhova

G.K.

, Kranzhofer

Macrophage foam cells from experienced atheroma constitutively produce matrix-dependent proteinases.

Proc Natl Acad Sci USA 1995; 92: 402–6.

19.

Brown

D.L.

, Hibbs

M.S.

, Kearney

Identification of 92-kDa gelatinase in human coronary atherosclerotic lesions. Association of active enzyme synthesis with unstable angina.

Circulation 1995; 91: 2125–31.

20.

Sukhova

G.K.

, Schonbeck

, Rabkin

Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques.

Circulation 1999; 99: 2503–9.

21.

Thompson

S.G.

, Kienast

, Pyke

S.D.M.

for the European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995; 332: 635–41.

22.

Maseri

, Biasucci

L.M.

, Liuzzo

Inflammation in ischaemic heart disease. C-reactive protein concentrations may provide useful information on risk.

BMJ 1996; 312: 1049–50.

23.

Ridker

P.M.

, Glynn

R.J.

, Hennekens

C.H.

C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction.

Circulation 1998; 97: 2007–11.

24.

Haverkate

, Thompson

S.G.

, Pyke

S.D.

for the European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Production of C-reactive protein and risk of coronary events in stable and unstable angina. Lancet 1997; 349: 462–6.